Flare Therapeutics appoints Douglas Manion as CEO

Cambridge, USA-based biotech Flare Therapeutics (FlareTx) has appointed Douglas Manion as chief executive, effective immediately.

Dr Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies. He succeeds interim CEO Abbie Celniker, a partner at Third Rock Ventures, who will continue to serve as chairwoman of the company’s board of directors.

“I am delighted to welcome Doug to FlareTx and want to express my deepest confidence in his ability to lead the company during this next stage of growth. Over the course of his career, he has gained substantial company building and drug development expertise, which will be invaluable as FlareTx continues to grow as an organization and advances its clinical-stage pipeline and capabilities in drugging transcription factors,” said Dr. Celniker. “I look forward to working with him and the leadership team as they drive the company’s strong momentum.”